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Background: Macrophages are pivotal in coordinating a range of important processes
in the intestines, including controlling intracellular infections and limiting damaging
inflammation against the microbiota. However, it is not clear how gut macrophages,
relative to recruited blood monocytes and other myeloid cells, contribute to the intestinal
inflammatory milieu, nor how macrophages and their monocyte precursors mediate
recruitment of other immune cells to the inflamed intestine.
Methods: Myeloid cell populations isolated from colonic inflammatory bowel disease
(IBD) or murine dextran sulphate sodium (DSS) induced colitis were assessed using flow
cytometry and compared to healthy controls. In addition, mRNA expression profiles in
human and murine colon samples, and in macrophages and monocytes from healthy
and inflamed murine colons, were analysed by quantitative PCR (qPCR) and mRNA
microarray.
Results: We show that the monocyte:macrophage balance is disrupted in colon
inflammation to favour recruitment of CD14+HLA-DRInt cells in humans, and Ly6CHi
monocytes inmice. In addition, we identify that murine bloodmonocytes receive systemic
signals enabling increased release of IL-1β prior to egress from the blood into the
colon. Further, once within the colon and relative to other myeloid cells, monocytes
represent the dominant local source of both IL-1β and TNF. Finally, our data reveal that,
independent of inflammation, murine colon macrophages act as a major source of Ccl7
and Ccl8 chemokines that trigger further recruitment of their pro-inflammatory monocyte
precursors.
Conclusions: Our work suggests that strategies targeting macrophage-mediated
monocyte recruitment may represent a promising approach for limiting the chronic
inflammation that characterises IBD.
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INTRODUCTION
The gastrointestinal (GI) tract is exposed to the greatest antigenic
burden in the body, which poses a significant challenge to the
many resident immune cells (1). Macrophages form the largest
component of the intestinal mononuclear phagocyte system and
play a pivotal role in mediating immune homeostasis (2). The
IBDs, including ulcerative colitis (UC) and Crohn’s disease (CD),
are characterised by a disturbed immunological homeostasis in
genetically susceptible individuals, although the exact aetiology
is unknown (3–5).
It has recently been shown thatmurine intestinalmacrophages
are continually repopulated from circulating blood monocytes,
identified by expression of the cell surface markers Ly6C, CCR2,
and CD62L (6). However, the functions of mature intestinal
macrophages and recruited monocytes are strikingly different.
Intestinal macrophages display a “tolerant” phenotype, poorly
responsive to toll like receptor (TLR) ligands (vital to avoid
triggering inflammatory responses while scavenging commensal
bacteria) whilst maintaining a homeostatic environment via
IL-10 and PGE2 production (7). In contrast, murine colon
monocytes are pro-inflammatory but infrequent in the steady
state, increasing during inflammation (2, 8–10).
Previous studies have shown the accumulation of human
CD14Hi or CD14+HLA-DRInt cells in the GI tract lamina propria
(LP) during inflammation (2, 6, 11–14). Results from murine
studies (2) combined with the observation of radiolabelled blood
monocytes in the inflamed intestinalmucosa of IBD patients (15),
indicate that increased LP inflammatory mononuclear cells are a
result of monocyte recruitment, rather than expansion of a tissue
resident macrophage population. Therefore, as monocytes and
macrophages are considered potential cellular targets for therapy
in limiting damaging host responses in intestinal disease (16),
there is an urgent need to improve the resolution of these events
in the mucosal tissue.
The surface phenotype of immune cells is dependent on their
location in the GI tract, which is critical when interpreting
previous studies. For example, both small intestine and colon
macrophages display high expression of MHC-II, CD163, and
(in mice) CX3CR1, while colon macrophages express greater
levels of acid phosphatase, CD40, CCR5, and formyl peptide
receptor (17–19). Similarly a recent seminal study of genotype-
phenotype in IBD highlighted how disease location in the
GI tract strongly correlates with genetic susceptibility (20).
As such, the mechanisms underlying intestinal inflammation
are likely to vary depending on the GI tract location, for
example small intestine vs. large intestine. Human data thus
far has been largely limited to combined surgical resections
from both large and small intestine from IBD patients or
healthy patients undergoing resection for another indication
(such as urostomy formation) (2, 12, 14, 21, 22). Therefore,
it is not clear which facets of the colon immune response
contribute to the inflammatory phenotype previously reported
for IBD.
We have utilised targeted human colon biopsies to assess
monocyte:macrophage balance during colon inflammation in
patients with IBD vs. healthy controls, alongside complementary
work using the murine DSS model of colitis. A combination
of multi-parameter flow cytometry, qPCR, and mRNA
microarrays were used to define disruption of the resting
monocyte:macrophage balance, with influx of CD14+HLA-
DRInt cells or Ly6CHi monocytes in humans and mice,
respectively.
Whilst monocytes are thought to be important inflammatory
cytokine producing cells, their contribution to the inflammatory
milieu relative to other myeloid cells in the gut is not known.
We show that in murine colitis, colon monocytes represent
the key myeloid source of IL-1β. Although TNF+ monocytes
also expanded in response to DSS, overall TNF+ myeloid
cells were less frequent than IL-1β+ cells. In addition, blood
monocytes produced significantly greater IL-1β but not TNF
during DSS colitis when stimulated with LPS, suggesting this
pro-inflammatory potential is enhanced even before leaving the
blood.
Further, we have defined for the first time transcriptomic
differences associated with monocyte-macrophage maturation
and inflammation in murine colon macrophage and monocyte
populations from steady state and DSS colitis. Intriguingly, the
genes most up-regulated comparing monocytes to macrophages
were conserved in both steady state and inflammation and
represented chemokines that promote monocyte recruitment,
including Ccl7, Ccl8, and Ccl12 (9, 23). Lastly, we show that CCL7
and CCL8 were also markedly elevated in human biopsy material
from active IBD.
Together, this suggests that in both humans and mice the
tolerogenic status quo of steady state macrophages is overturned
during colon inflammation to promote recruitment of their
potent pro-inflammatory monocyte precursors.
MATERIALS AND METHODS
Mice
Female C57BL/6 wild-type (WT) mice aged 12–22 weeks
were maintained under specific pathogen free conditions (SPF)
at the University of Manchester, in compliance with the
United Kingdom Animals (Scientific Procedures) Act 1986.
CX3CR1+gfp mice were maintained under SPF conditions at the
Central Research Facility, University of Glasgow (24).
DSS Model
Mice received 2% DSS salt (reagent grade MW 36,000–50,000
kDa; MP Biomedicals, Solon OH) ad libitum in sterile drinking
water for 6 days, as described previously (2).
Patients and Tissues
Flow Cytometry
Thirteen IBD (UC or CD) patients undergoing colonoscopy
for disease assessment had biopsies taken from endoscopically
inflamed (active IBD; 6 samples from 6 patients) or non-inflamed
(quiescent IBD; 10 samples from 7 patients) colon in addition
to 4 patients attending for colonoscopy for assessment of IBS
symptoms (healthy controls; 4 samples from 4 patients) for flow
cytometry analysis. In those patients with quiescent IBD that had
more than one biopsy analysed, these were from discrete gut
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segments >10 cm apart as described in Table 1. Healthy control
patients had a normal colonoscopy, had no other past medical
history and were not ultimately diagnosed with any GI tract
pathology (Table 1).
RT-qPCR
A separate group of 28 IBD (UC or CD) patients undergoing
colonoscopy for disease assessment had biopsies taken from
endoscopically inflamed (active IBD; 19 samples from 17
patients) or non-inflamed (quiescent IBD; 12 samples from
11 patients) colon in addition to eight patients attending
for colonoscopy for assessment of IBS symptoms (healthy
controls; 12 samples from 8 patients) for RNA extraction
and RT-qPCR analysis. Where more than one biopsy was
analysed, these were from discrete gut segments >10 cm apart
as described in Supplementary Table 1. Healthy control patients
had a normal colonoscopy and had no other past medical
history, with only one patient ultimately given a diagnosis
of IBS (Supplementary Table 1). Montreal classification and
drug information were derived from review of patient records
(Table 1; Supplementary Table 1).
Isolation of LP Cells
LP cells were obtained from mouse colon by enzymatic
digestion as described previously (2). Human colon biopsies were
incubated in Hank’s balanced salt solution (HBSS), 1% Penicillin-
streptomycin (PenStrep) (Sigma-Aldrich), G418 (Melford) and
1mM DTT (Sigma-Aldrich) for 15min followed by three 15min
washes at 37◦C with rotation (200 rpm) with HBSS, PenStrep,
G418 and 1mM EDTA (Sigma-Aldrich) to remove epithelial
cells. The tissue was then digested in 1 mg/ml Collagenase A
(Roche) in 10% FCS RPMI, 1% PenStrep and G418 with 60 U/ml
DNAse I (Sigma-Aldrich) for 1 h in a shaking incubator at 37◦C.
After this time, the tissue was strained through a 40µMfilter, and
cells analysed by flow cytometry or lysed in RLT buffer (Qiagen)
for RNA extraction.
Flow Cytometric Analysis and Sorting of
Cells
0.5–2 × 106 cells were stained at 4◦C as described previously
using the antibodies listed in Supplementary Table 2 (6). To
detect intracellular cytokines, cells were incubated in complete
RPMI (Sigma-Aldrich plus 10% FCS 1% PenStrep) at 37◦C in
TABLE 1 | Flow cytometry colon biopsy sample patient demographics.
Disease category IBD Patient ID # Sex Age Montreal classification Biopsy location Drugs
Crohn’s disease UC IM Other
Age Location Behaviour
Normal – 1 M 42 Sigmoid
Normal – 2 F 39 Sigmoid
Normal – 3 F 56 Sigmoid
Normal – 4 F 47 Sigmoid
Quiescent CD 5 M 41 A1 L3 B1 Transverse AZA, IFX
Quiescent CD 6 F 35 A2 L3 B1 Transverse
Quiescent CD 6 F 35 A2 L3 B1 Rectum
Quiescent CD 7 M 42 A1 L3 B2 Transverse
Quiescent CD 7 M 42 A1 L3 B2 Sigmoid
Quiescent CD 8 F 27 A2 L3 B1 Transverse
Quiescent CD 8 F 27 A2 L3 B1 Sigmoid
Quiescent UC 9 F 65 E1 Rectum
Quiescent UC 10 M 45 E1 Rectum
Quiescent UC 11 F 27 E2 Sigmoid
Active CD 12 M 49 A1 L3 B2 Ascending
Active CD 13 M 27 A2 L2 B1 Ascending MTX, ADA
Active CD 14 M 52 A2 L3 B2 Transverse AZA
Active CD 15 M 30 A1 L3 B1 Transverse
Active UC 16 M 27 E3 Rectum AZA 5′ASA
Active UC 17 F 27 E2 Rectum
13 IBD (UC or CD) patients undergoing colonoscopy for disease assessment had biopsies taken from endoscopically inflamed (active IBD; 6 samples from 6 patients) or non-inflamed
(quiescent IBD; 10 samples from 7 patients) colon in addition to four patients attending for colonoscopy for assessment of IBS symptoms (healthy controls; 4 samples from 4 patients)
for flow cytometric analysis. Patient records were reviewed for demographic, IBD location and disease behaviour by Montreal classification. IM, Immunomodulatory drugs; MTX,
methotrexate; ADA, adalimumab; IFX, infliximab; 5′ASA, 5′aminosalicylic acid. Montreal classification for CD: A1, age at onset <16 years; A2, between 17 and 40 years; A3, >40 years.
L1, ileal disease location; L2, colonic disease location; L3, ileocolonic disease location. B1, inflammatory phenotype; B2, stricturing phenotype; B3, penetrating phenotype. Montreal
classification for UC: E1, proctitis; E2, rectosigmoid disease; E3, disease proximal to the splenic flexure. CD, Crohn’s disease, UC, ulcerative colitis. # Patient ID is the identifier allocated
to each individual providing tissue, such that donors that gave more than 1 sample can be identified.
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5% CO2 for 3 h in the presence of 1 µl/ml GolgiStop (BD
Biosciences). After surface staining, cells were fixed in 1%
paraformaldehyde, washed in phosphate-buffered saline (PBS)
and permeabilised using Cytofix/Cytoperm (BD Biosciences).
After a further stain with PE anti-TNF and FITC anti-IL-1β
or isotype controls for 1 h, cells were washed prior to
sample acquisition. All stained samples were acquired using
a LSRFortessa (BD Biosciences) and analysed using FlowJo
software (TreeStar, Ashland, OR). The number of myeloid cells
per mouse colon was determined by calculating the proportion
of the identified populations (Figure 2A) as a proportion
of Live/singlet/intact/CD45+/Lineage− cells. The sum of the
populations expressed in Figure 2A accounted for>97% of these
cells. Myeloid population data was then expressed per mouse
colon using the total cell count derived after purification.
Macrophage and monocyte populations were purified
using fluorescence-activated cell sorting (FACS) for
subsequent gene expression analysis. In the steady
state, CD45+CD11b+CX3CR1IntLy6C+MHC-II−
monocytes and CD45+CD11b+CX3CR1HiLy6C−MHC-
II+F4/80+ macrophages were purified from CX3CR1-
GFP mice as previously described (2). In DSS colitis,
CD45+Ly6G−Siglec-F−CD11b+Ly6C+MHC-II+/− monocytes
and CD45+Ly6G−Siglec-F−CD11b+Ly6C−MHC-II+F4/80+
macrophages were sorted from C57BL/6 mice that had been
exposed to DSS for 6 days.
Murine Blood Monocyte Isolation
Blood was obtained by cardiac puncture and combined with 200
µl of 2mM EDTA 3% FCS in PBS to prevent coagulation. Serum
was aspirated after pelleting of whole blood at 500G, 4◦C for
5min before re-suspension of haematocrit in 5ml red cell lysis
buffer (Sigma-Aldrich) for 7min to lyse red blood cells. 2 × 106
cells were incubated for 3 h at 37◦C, 5% CO2 with 1 ug/ml LPS
(Sigma-Aldrich) before surface/intracellular staining for CD68,
CD11b, Ly6C, Lineage markers (NK1.1, CD19, CD3, Ter119,
B220), IL-1β and TNF.
mRNA Microarray and Quantitative PCR
(qPCR)
For murine colon samples or sorted cell populations total RNA
was purified using RNeasy mini kits (Qiagen), as previously
described (25). For microarrays, RNA was labelled using
TotalPrep RNA amplification kits (Life Technologies) and
hybridised with Illumina MouseWG-6BeadChip arrays with
five biological replicates from one experiment of FACS-purified
macrophages and monocytes. The microarray data from the
naïve mice were retrieved from the GEO data set GSE84764 (26).
All analyses were conducted in R using Bioconductor. Pairwise
group comparisons were undertaken using linear modeling.
Subsequently, empirical Bayesian analysis was applied, including
vertical (within a given comparison) P-value adjustment for
multiple testing, which controls for false-discovery rate, using the
limma Bioconductor package.
For RT-qPCR of colon tissue, RNA was extracted using
RNeasy mini kits (Qiagen) and complementary DNA was
generated using GoScript reverse transcriptase kits (Promega).
Relative quantification of genes of interest was performed
by qPCR analysis using QuantStudio 12 Flex Real Time
OCR system, with Fast SYBR R© Green Master Mix (Life
Technologies), compared with a serially diluted standard
of pooled complementary DNA. Transcript expression was
normalised to the housekeeping gene GAPDH, which did not
vary significantly during inflammation (data not shown). Primers
are listed in Supplementary Table 3.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism
v.7 or JMP v.12 (SAS Institute). The data were checked to
confirm normality and that groups had equal variance. One-way
analysis of variance (ANOVA) with Tukey’s multiple comparison
tests was employed to determine significant differences between
sample groups. Results from these tests were reported as
significant if P < 0.05, with results from these tests shown
as mean ± SEM. For some experiments statistical analysis
was carried out using JMP, in which case data were analysed
using three-way full-factorial fit models to assess effects, such
as “genotype,” “treatment,” and “experiment” on the response
variable of interest. This allowed the interaction between effects
to be taken into account in addition to their impact on the
response variable, which enabled experimental repeats to be
pooled increasing the power of the analysis (27). The least squares
mean results table from the three-way full-factorial analysis was
used to test the contrast between specific experimental groups
using a joint F-test. A difference between experimental groups
was taken to be significant if the P-value (Prob > F) was < 0.05,
with results in graphs shown as least squares mean± SEM.
Ethical Considerations
All samples were obtained according to the principles expressed
in the Declaration of Helsinki and under local ethical guidelines
and approved by the North West National Research Ethics
Service (reference number 15/NW/0007). All patients provided
written informed consent for the collection of tissue samples and
subsequent analysis.
RESULTS
Active Human Colon IBD Is Characterised
by Recruitment of CD14HiHLA-DRInt Cells
A dominant feature of IBD is damaging local production of pro-
inflammatory cytokines (28). Indeed, long-term administration
of monoclonal antibodies against TNF still forms the mainstay
of treatment for patients with complicated disease (29, 30).
Polymorphisms in IL1B, IL6, and TNF have all been associated
with predisposition to IBD, suggesting variation in the ability
to regulate pro-inflammatory cytokine production is associated
with disease susceptibility (31). We therefore used qPCR to assess
the mRNA expression “signature” of key inflammatory genes
in targeted colon biopsy samples of macroscopically inflamed
or quiescent areas from patients with IBD, or from healthy
controls (Figure 1A; Table 1). Consistent with expectation,
mRNA transcripts for TNF, IL1B, and IL6 were significantly
increased in active IBD vs. quiescent IBD or healthy control
patient samples, confirming that these cytokines are a hallmark
Frontiers in Immunology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 2764
Jones et al. Monocyte/Macrophage Activation During Colitis
FIGURE 1 | Disruption of resting CD14Hi:CD14Lo populations in active IBD. Patients with IBD had colonic biopsies taken from macroscopically inflamed (active IBD)
or non-inflamed (quiescent IBD) areas and compared to sigmoid colon biopsies from healthy controls. (A) mRNA isolated from biopsy samples was analysed by qPCR
for expression of IL1B, IL6, and TNF with mean values relative to GAPDH shown (12 healthy control, 12 quiescent IBD, and 19 active IBD biopsy samples from
(Continued)
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FIGURE 1 | 8, 11, and 17 healthy control/patients, respectively were analysed in three separate experiments, representative data shown) (Supplementary Table 1).
(B,C) Colon lamina propria cells were isolated from an additional 4 healthy control, 10 quiescent IBD and 6 active IBD biopsy samples (from 4, 7, and 6 healthy
control/patients, respectively) and analysed by flow cytometry (Table 1). (B) Live, singlet, Lineage− (CD3, CD19, CD20, CD56) cells were then assessed for the
expression of CD14, CD45, CD11c, CD64, CD163, and HLA-DR. Ratios of CD14Hi to CD14Lo, Lineage−CD45+ and CD14Hi HLA-DRHi to HLA-DRint cells were
compared in biopsy samples. (C) Histograms of CD163 and CD64 in CD14Hi and CD14Lo healthy controls (left and middle panel) and HLA-DR in CD14Hi populations
from active and quiescent IBD (right panel) *P < 0.05, **P < 0.01, ****P < 0.001. a.u., arbitrary units.
of disease activity (Figure 1A) and this was unaffected by drug
treatment.
We hypothesised that the balance of tolerogenic steady state
macrophages vs. pro-inflammatory monocytes likely defines
resting and inflamed human colon tissue, particularly given
that these populations have been shown to be in continuum
in murine studies (2, 6). We therefore compared proportions
of macrophages and monocytes in inflamed vs. quiescent colon
biopsies. Though distinction between intestinal macrophages
and monocytes is more challenging in humans than in mice,
recent work has shown that there is significant conservation
of markers that also define murine intestinal macrophages,
such as CD14, CD64, CD68, MHC-II, and CD163 (2, 13,
18, 31). Indeed, as in mice where maturity of resident colon
macrophages is inversely associated with expression of Ly6C,
human macrophages are thought to express low levels of CD14
(CD14Lo) whilst there also exists a smaller CD14Hi subset
that is more heterogeneous for expression of CD163, HLA-
DR, and CD209 and may represent the Ly6C+ monocytes in
mice (2). We therefore used a combination of CD14 and HLA-
DR expression to define human monocyte/macrophage subsets
(Supplementary Figure 1A) and found that, when comparing
CD14+ populations, CD14LoHLA-DRHi cells were most frequent
in the steady state, with a much lower proportion of CD14Hi
cells (Figure 1B). Notably, in line with their designation as part
of the macrophage lineage, both these populations expressed
high levels of CD64 and CD163 (Figure 1C). We found that
patients with active IBD displayed a striking accumulation of
CD14Hi cells, compared to both quiescent IBD and healthy
control individuals (Figure 1B), and this was unaffected by drug
treatment. Notably, whereas CD14Hi cells in healthy control and
quiescent IBD samples expressed high levels of HLA-DR, CD14Hi
cells found in active IBD had a HLA-DRInt/Hi profile, consistent
with a more immature state (Figures 1B,C). In contrast, whilst
the proportion of CD14Lo macrophages was largely unchanged in
inflammation, the ratio of CD14Hi:CD14Lo cells was significantly
altered, due to the accumulation of a CD14HiHLA-DRInt/Hi
population (Figures 1B,C).
Thus, we have shown in a targeted biopsy dataset from a colon
IBD cohort that, analogous to the changes that have previously
been described in mice (9), the balance of human colon intestinal
CD14Lo macrophages is perturbed in active IBD, favouring the
accumulation of CD14HiHLA-DRInt monocyte-like cells.
Murine Colitis Is Characterised by
Recruitment of
CD11b+Ly6C+CD11c−MHC-II+/−
Monocytes
To interrogate the molecular mechanisms underpinning the
dysregulated CD14Hi:CD14Lo axis and cellular sources of IL-1β
and TNF in colon inflammation we had observed in human
biopsy material, and its contribution to colon inflammation, we
employed the use of an establishedmodel of murine experimental
colitis. DSS colitis is characterised by disruption of the colon
epithelial barrier and subsequent inflammation directed towards
the infiltrating microbiota (32, 33). This process is dependent
on intestinal microbial colonisation and independent of T and
B cells, permitting definition of innate immune cell involvement
(33, 34) However, the monocyte:macrophage balance and
comparative cytokine production during the propagation of
DSS colitis is not well-defined, even though these innate cells
have been heavily implicated in development of inflammatory
pathology in this model (2, 9, 35, 36). Use of multi-parameter
flow cytometry (Figure 2A) showed that, similar to healthy
human biopsies (Figure 1B), the mouse colon contained a
large population of macrophages (defined as F4/80+MHC-
II+CD64+CD11b+) and a small population of monocytes
(Ly6C+CD11b+MHC-II+/−; Figure 2B) (6). This balance was
disrupted inDSS-induced colitis, which led to a dramatic increase
in monocytes (Figure 2C). Assessment of the entire myeloid
cell compartment revealed that neutrophils (CD11b+Ly6G+)
and monocytes underwent the greatest numerical increase (9.2
and 3.7-fold change, respectively), followed by eosinophils
(SSCHiSiglec-F+, 2.2-fold change) and dendritic cells (DCs)
(CD11c+F4/80LoCD64−, 2.3-fold change). In contrast, the
change in macrophage numbers was less dramatic (1.3-fold
change) following DSS treatment (Figure 2C—left). Thus, as
a proportion of all myeloid cells, inflammation induced an
increase in monocytes, neutrophils and eosinophils, alongside
reduced proportions of DCs and macrophages, compared to
the steady state (Figure 2C—right). This shows that, as we
observed in active human IBD, murine colitis is characterised by
a striking disruption of the resting monocyte:macrophage ratio
(Figures 1B, 2B).
Colon Monocytes in Murine Colitis Express
High Levels of IL-1β and TNF
The pro-inflammatory cytokines IL-1β and TNF are highly
expressed in the mucosa of patients with active IBD (Figure 1A)
(37). Further, although mice treated with IL-1β neutralising
antibodies display reduced DSS inflammation and expression of
IL-6 mRNA transcripts, TNF levels are unaltered (37), indicating
that IL-1β may play a more dominant role in promoting DSS
colitis than TNF. Recent evidence suggests that perhaps non-
monocyte sources of IL-1β may be important in C. rodentium
infection, as chimeric mice (CCR2WT/Il1b−/− vs. CCR2WT)
where 50% of monocytes lack the ability to produce IL-1β
(1:1 mix CCR2WT/Il1b−/−) still produce what appears to be
equivalent IL-1β in colon LP supernatant to CCR2WT (38). As
such, monocyte egress from the blood to the intestines could be
Frontiers in Immunology | www.frontiersin.org 6 November 2018 | Volume 9 | Article 2764
Jones et al. Monocyte/Macrophage Activation During Colitis
FIGURE 2 | Cytokine production in murine blood and colon monocytes. WT mice received 2% DSS in drinking water (or control drinking water) for 6 consecutive
days, colon lamina propria cells and the cellular component of blood was isolated and assessed for the expression of Siglec-F, Ly6G, CD11b, CD11c, F4/80, CD45,
(Continued)
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FIGURE 2 | and Lineage markers (CD3, CD19, NK1.1, Ter119) (colon) or Ly6C, Lin (NK1.1, CD19, CD3, Ter119, B220), CD11b and CD68 (blood) by flow cytometry.
(A). Representative flow cytometry contour plots in day 6 DSS treated WT mice of Live/singlet/Lineage−CD45+ cells. (B). Least square mean ratio of total number of
colon LP Monocytes:Macrophages identified from (A) in DSS and drinking water controls (C). The least square mean total number of cells per colon for the
populations in (A) (left) and their relative proportions (right), n = 15–25 per group, analysed by linear regression of six independent experiments. The least square mean
total number of cells per colon (D)-left and (F)-left, proportion of all, (D)-right and (F)-right, and percentage of total population (E) and (G) expressing IL-1β (D) and (E)
or TNF (F) and (G) after 3 h incubation with 1 µl/ml GolgiStop for the populations in (A) as assessed by intracellular staining and flow cytometry compared to isotype
antibody control, n = 12–15 mice per group analysed by linear regression of three independent experiments. (H). Representative flow cytometry plots of blood
monocytes isolated from day 6 DSS treated or drinking water controls stimulated with 1µg/ml LPS and GolgiStop 1 µl/ml for 3 h and assessed for the expression of
IL-1β by intracellular staining, with the least mean square % of total blood monocytes (I), n = 12–15 mice per group analysed by linear regression of three
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, #P < 0.0001 for total cell number vs. controls.
hypothesised to stimulate IL-1β production from non-monocyte
sources (38). We therefore directly compared ex vivo pro-
inflammatory cytokine production by monocytes, macrophages
and other myeloid cells in steady state and following DSS
administration, using flow cytometry to assess intracellular IL-1β
and TNF protein levels. There were significant increases in the
absolute number of IL-1β+ macrophages, DCs, monocytes and,
to a lesser extent, neutrophils (Figure 2D). However, monocytes
accounted for the largest increase following DSS administration,
in both absolute numbers (12.2-fold change) and proportion, to
represent 35.7% of all IL-1β+myeloid cells (Figure 2D). Not only
were IL-1β+ monocytes more numerous in DSS colitis, but the
proportion of monocytes expressing IL-1β increased significantly
(1.9-fold to 51.7% of all monocytes), which was greater than any
other IL-1β expressing myeloid population (Figure 2E). Thus,
although there were diverse myeloid sources of IL-1β during DSS
colitis, monocytes were the most responsive and prominent IL-
1β+ population, undergoing the greatest numerical and per cell
changes in this setting. As such, the impact of colon monocytes
on inflammation during DSS colitis is likely a compound effect
of increased per cell IL-1β production along with increased
recruitment.
Compared to IL-1β+, there were far fewer intestinal
myeloid cells that were TNF+ in steady state or during DSS
colitis (compare Figures 2D,F). Macrophages were the most
dominant TNF+ population, independent of inflammation, but
demonstrated only small changes in total number following
DSS administration. As seen with IL-1β secretion, of the TNF+
myeloid cell subsets, monocytes expanded the most after DSS
administration (5.6-fold change), and increased in proportion to
represent 21.1% of all TNF+ myeloid cells. However, in contrast
to IL-1β, there was no significant increase in the proportion of
monocytes that expressed TNF.
Blood Monocytes in Murine Colitis Are
Conditioned to be Pathogenic Before
Arrival Into Inflamed Tissue Sites
Given that the proportion of murine colon IL-1β+ monocytes
increased more dramatically than any other myeloid population
in DSS (Figure 2E), we questioned whether this reflected an
increased ability of monocytes to respond to an inflamed
micro-environment, and/or a result of being primed to
be pro-inflammatory systemically prior to arrival in the
mucosa. To address this, we cultured monocytes isolated
from the blood of DSS treated or control mice ex vivo in the
presence, or absence, of LPS and assessed their production
of pro-inflammatory IL-1β and TNF using intracellular
flow cytometry. Ly6CHiCD11b+CD68+ blood monocytes
from DSS treated animals displayed a significantly greater
proportion of cells expressing IL-1β, but not TNF (Figures 2H,I;
Supplementary Figure 1B), similar to the responses observed
from colon monocytes (Figures 2E,G). In addition, neither IL-1β
nor TNF were detectable in blood monocytes in the absence of
LPS stimulation, suggesting negligible levels of basal cytokine
expression.
Murine Colon Inflammation Changes
Expression of Similar ER Stress Response
Genes in Both Macrophages and
Monocytes
We next sought to understand how the disrupted
monocyte:macrophage balance we had identified in both
murine and human colitis related to altered gene expression by
these key myeloid cells. Colon LP macrophages and monocytes
were purified by FACS from control and DSS treated mice, RNA
extracted and analysed by transcriptome microarray. Firstly,
we looked at the effect of colon inflammation on monocyte
and macrophage mRNA expression. By comparing populations
from DSS treated vs. naïve mice, we identified 1,446 genes in
macrophages (924 down- and 522 up-regulated) and 1,284
genes in monocytes (858 down- and 426 up-regulated) that
were significantly altered (Log2-fold change ≥ 2, P < 0.01;
Figure 3A). Of these, 151 of the 200 most differentially expressed
genes (i.e., the largest absolute fold 100 up- and 100 down-
changing genes) were the same in both macrophages and
monocytes (DSS vs. naïve). This suggested that inflammation
confers similar mRNA expression changes in both intestinal
macrophages and monocytes. The greatest fold change in gene
expression were in mRNA transcripts of ribosomal proteins and
ER stress (Eif3k, Rpl13a, Rpl31, Rpl37) changes in all of which
were similar in both macrophages and monocytes (Figure 3B)
(39–41). Indeed, KEGG analysis showed that the most significant
pathway was “protein processing in the ER” which was the
down-regulated after DSS in both monocytes and macrophages
(Figure 3C).
Murine Colon Monocyte to Macrophage
Maturation Changes Chemokine Gene
Expression Irrespective of Inflammation
We next looked at the effect of monocyte to macrophage
maturation on mRNA expression profiles from naïve or DSS
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FIGURE 3 | Chemokine expression is increased in inflamed murine colon macrophages and active human IBD. Colon lamina propria macrophage and monocyte
populations were isolated and purified by flow cytometry from day 6 2% DSS (CD11b+MHC-II+Lineage−Ly6C− macrophages, CD11b+MHC-II+/−Lineage−Ly6C+
(Continued)
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FIGURE 3 | monocytes) or naïve mice. RNA was extracted, and gene expression assessed by hybridisation to IlluminaMouseRef6 microarray (2% DSS) or Affymetrix5
chip (Naïve). (A). Volcano plots of Log10 significance and Log2-fold change for gene expression comparisons of DSS vs. naïve macrophages and monocytes. (B).
Heat map of selected normalised gene expression from (A) (adjusted P < 0.01) each individual heatmap represents a biological replicate composed of 2–5 pooled
mice. (C) KEGG pathway analysis of significant (adjusted P < 0.01) pathways from (A). (D). Volcano plots of Log10 significance and Log2-fold change for gene
expression comparisons of monocytes vs. macrophages in DSS and steady state. (E). Heat map of selected normalised gene expression from D (adjusted P < 0.01)
each individual heatmap represents a biological replicate composed of 2–5 pooled mice. (F) KEGG pathway analysis of significant (adjusted P < 0.01) pathways from
(D). (G). Patients with IBD had colon biopsies taken from macroscopically inflamed or non-inflamed areas and compared to biopsies from healthy controls. mRNA
isolated from biopsy samples was analysed by qPCR for expression of CXCL1, CCL7 and CCL8 with mean values relative to GAPDH shown (12 healthy control, 12
quiescent IBD, and 19 active IBD biopsy samples from 8, 11, and 17 healthy control/patients, respectively were analysed in three separate experiments,
representative data shown) (Supplementary Table 1). *P < 0.05, **P < 0.01,***P < 0.001, ****P < 0.0001. a.u., arbitrary units.
treated mice. Comparing gene expression of macrophages vs.
monocytes from DSS mice revealed 44 genes (27 down- and
17 up-regulated) and 308 genes from naïve mice (196 down-
and 112 up-regulated) were Log2-fold change ≥ 2 expressed
(P < 0.01; Figure 3D). Once again there was a striking similarity
independent of inflammation with 73/200 of the 100 largest
absolute fold changing up- and down-regulated genes identical
in steady state and DSS when comparing macrophage vs.
monocyte gene expression. The genes most highly expressed
in macrophages relative to monocytes in both health and
inflammation were chemokines (Figures 3E,F). In particular
macrophage mRNA expression of Ccl7, Ccl8, Ccl12, and Cxcl1
was greatly elevated compared to monocytes, in both naïve and
inflamed settings (Figure 3E). This suggests that in the colon,
monocyte-derived macrophages rapidly develop the capability
to produce chemokines that would facilitate recruitment of
both their own monocyte precursors and neutrophils (39), with
high level expression of these genes conserved in macrophages
independent of inflammation. In addition, comparison of
monocytes from DSS vs. naïve mice showed elevated expression
of Ccl7, Ccl8, and Cxcl1 upon inflammation (Figure 3E).
Surprisingly, Ccl2 and Ccl3, which are crucial mediators of
monocyte and macrophage recruitment, were not expressed
at significantly different levels comparing monocytes to
macrophages, either in the steady state or during inflammation
(Figure 3E) (7, 9, 38, 40). In fact, levels of these transcripts
were actually significantly reduced in both monocytes and
macrophages when comparing inflamed to naïve settings
(Figure 3E).
Having identified a distinctive chemokine signature in
myeloid cells isolated from murine colitis, we next sought to
assess whether a similar pattern of altered chemokine expression
was evident during human colitis. Targeted colon biopsies from
control, quiescent IBD and active IBD were analysed for mRNA
expression of CCL7, CCL8, and CXCL1 based on our murine
array data. As in murine colitis, CCL7, CCL8, and CXCL1 were
all significantly increased in active IBD vs. quiescent IBD and
controls (Figure 3G).
These data show the comparative effects of intestinal
inflammation on the mRNA signatures of colon monocytes
and macrophages, identifying altered expression in both
macrophages and monocytes of genes that stabilise ribosome
function during ER stress incurred by inflammation and
chemokines involved in promoting monocyte recruitment
incurred by monocyte-macrophage differentiation.
DISCUSSION
IBD is characterised by remitting relapsing inflammation of
uncertain pathogenesis that in CD can occur anywhere in the
GI tract and in UC occurs almost exclusively in the colon.
However, existing data on the innate immune system in IBD has
predominately focused on phenotyping immune cells from the
small intestine, in isolation or a combination of small and large
intestine, rather than the colon exclusively (2, 12, 14, 21, 22).
Even within murine colitis models, the changes conferred by
inflammation on the relative abundance of different myeloid cells
and their relative frequency, proportion and cytokine responses
are poorly described. Our study utilised both targeted biopsy
material from a colon IBD cohort and a murine model of colitis,
to show that inflammation dramatically altered the composition
of the myeloid compartment in the colon.
Naïve colon monocytes quickly differentiate into resident
macrophages after entering the intestine, a process that
confers significant change in function towards tolerance of the
microbiota (2). However, comparison of the gene expression
changes that accompany the differentiation process in the steady
state vs. colon inflammation, or indeed the expression differences
of colon monocytes and macrophages before and after colitis, are
unknown.
We observed that active human colon IBD was associated
with significantly greater colon mRNA expression of TNF, IL1B,
IL6, and ratios of CD14Hi:CD14Lo and HLA-DRInt:HLA-DRHi
cells vs. quiescent IBD and healthy controls. This is consistent
with previous work that has reported an increase in CD14Hi cells
in inflamed intestinal mucosa that have features of less mature
mononuclear cells, though our data is one of the first using an
exclusive colon dataset of targeted biopsies comparing active and
quiescent IBD to healthy controls (14). Indeed, identifying the
role of intestinal CD14Hi cells has been hampered somewhat by
different methodologies (in particular differences in anatomical
location sampling) and sub-classification in the literature (2, 11–
14). As we were limited to assessment of healthy control sigmoid
colon alone in our presented work, future studies will be required
to address if IBD alters these populations to varying degrees in
different regions of the colon.
CD14HiHLA-DRHi cells from CD/UC surgical resection
specimens may induce differentiation of naïve T cells into Th17
cells with a CD163Lo subset able to produce greater IL-1β and
IL-6 after TLR stimulation, compared to macro/microscopically
normal areas from colon cancer resections (13). Similarly
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Kamada et al. reported an increase in IL-6, TNF, and IL-23
producing CD14+CD33+ cells in UC/CD surgical resection
specimens compared to controls, with both Thiesen et al.
(combined small and large intestine samples) and Magnusson
et al. (discrete small and large intestine samples) reporting
increased CD14HiHLA-DRInt cells in active vs. quiescent IBD
and healthy controls (11, 12, 14). This highlights that increased
numbers of CD14Hi intestinal cells in the colon may be a reliable
indicator of IBD severity.
Interrogation of a murine colitis model allowed us to
accurately define the numerical and proportional changes
in the colon myeloid compartment. Mirroring the increased
colonic CD14Hi:CD14Lo ratio observed in active human IBD,
murine colitis was characterised by an increased Ly6CHiCD64+
monocyte to Ly6C−CD64+F4/80+ macrophage ratio. Monocyte
and neutrophil populations were the most sensitive (by
fold change) to numerical expansion induced by DSS, with
corresponding significant decreases in the proportion of
macrophages and DCs within the myeloid compartment. Thus,
one of the hallmarks of murine and human colitis is the
accumulation of monocyte (mouse) or monocyte-like (human)
cells, such that they undergo a large numerical increase after the
onset of inflammation to represent a substantial proportion of the
myeloid compartment compared to the resting state.
In addition to identifying this link between severity of colitis
and increased tissue monocytes, we have shown for the first time
the relative production of the key inflammatory cytokines IL-
1β and TNF by intestinal myeloid cells in DSS colitis, revealing
monocytes as the dominant IL-1β producing population. This
was evident in both heightened per cell IL-1β production, and
increased IL-1β+monocyte numbers, compared to othermyeloid
cells. DSS did not increase per cell TNF production in any
myeloid cell population. Therefore, in contrast to IL-1β, the
increase in the number of TNF+ monocytes after DSS was
due to increased recruitment and accumulation of monocytes,
rather than increased per cell production of this cytokine.
The importance of IL-1β producing intestinal monocytes for
appropriate clearance ofCitrobacter spp has recently been shown,
where CCR2+ monocytes give rise to macrophages that induce
IL-22 from ILC3 cells in an IL-1β dependent manner (38).
Here we go further, having shown that during DSS colitis,
macrophages, DCs and neutrophils in the colon can produce
IL-1β in addition to monocytes.
In addition to assessment of tissue monocytes, we found
that murine blood monocytes produced heightened IL-1β, but
not TNF, during DSS colitis. This may indicate that intestinal
inflammation confers systemic signals to blood monocytes
increasing their IL-1β producing potential. In addition, neither
IL1-β nor TNF were detectable in the absence of LPS stimulation,
suggesting negligible levels of basal cytokine expression and that
monocyte pro-inflammatory cytokines would only be released on
tissue entry and TLR engagement. Whilst the specific systemic
signals that might confer increased blood monocyte IL-1β
potential are not yet known, it has recently been suggested that
NK cell production of IFN-γ can influence monocyte progenitors
in the bone marrow to adopt a regulatory phenotype during
acute gastrointestinal infection, a process that precedes the onset
of systemic inflammation (41). Indeed, granulocyte/monocyte
adsorption (GMA) columns are currently being investigated as a
therapy to reduce circulating CD14+CD16+ blood monocytes in
patients with active IBD (16). Interestingly, those patients treated
early with GMA display a more benign disease course, suggesting
that acute rather than established inflammation is more amenable
to monocyte intervention (42).
Whilst we have observed monocytes as a defining feature of
both murine and human colon inflammation, it is important to
note their macrophage-progeny are also thought to be important
constituents of the repair process. For example, Ccr2−/− mice
sequester monocytes within the BM (43), resulting in depletion of
tissue residentmacrophages, reducing their susceptibility to acute
DSS colitis but increasing susceptibility to chronic DSS mediated
inflammation (7, 44). Conversely conditional depletion of
CCR2+ monocytes using CCR2DTR mice increases susceptibility
to intestinal Citrobacter infection. This demonstrates the delicate
monocyte-macrophage balance required to repel intestinal
infection, limit potentially damaging monocyte recruitment and
also resolve tissue damage. Therefore, strategies aiming to
modulate pro-inflammatory monocytes during IBD may have a
“window of opportunity” in acute disease that must be balanced
against the importance of monocyte derived macrophages
in resolving chronic intestinal inflammation and monocytes
themselves in combatting opportunistic intestinal infection.
To identify the mechanisms that control monocyte and
macrophage abundance and their role in colitis, we compared the
mRNA profiles of purified colon monocytes and macrophages
from DSS treated and control mice. DSS conferred similar
changes to both monocyte and macrophage gene expression
compared to the steady state. Pathway analysis revealed top
dysregulated pathways in both populations were associated with
ER stress and unfolded protein response (UPR) associated loci
(Eif3k, Rpl13a down-regulated upon DSS and Rpl31 and Rpl37
up-regulated upon DSS). Eif3k for example encodes the k subunit
of the eurkaryotic initiation factor 3 (eIF3) which is an important
component of ER induced stress granules. Interestingly, the c
subunit of eIF3 (EIF3C) has been identified as a risk susceptibility
locus for IBD in early onset paediatric populations (45) and
eIF3 protein is found at increased levels in the colonic mucosa
of UC patients (46). This suggests decreased Eif3k mRNA
expression in monocytes/macrophages in our data is part of
a compensation mechanism for increased ER stress in these
populations during colitis (46). The other major down-regulated
gene, Rpl13a, encodes a ribosomal protein that forms part of
an IFN-γ activated inhibitor of translation (GAIT) complex that
binds untranslated regions of several cytokine mRNAs during
inflammation. Myeloid specific knockout of Rpl13a renders the
host susceptible to LPS-induced endotoxaemia and DSS colitis
(47, 48). Rpl13 deficient macrophages also display an unregulated
expression of CCL8, suggesting that the Rpl13a down-regulation
we observed in intestinalmacrophages is part of the host response
to the barrier breakdown caused by DSS that would permit
increased recruitment of cytokine producing inflammatory
monocytes (47). The function of other ribosomal proteins in
mediating macrophage/monocyte responses during colitis is
not well-characterised. However, Rpl31 and Rpl37, expression
of which were greatly increased by macrophages/monocytes
during DSS inflammation, have been implicated in cell cycle
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in bacteria and cancer, and preventing p53 mediated apoptosis
(49–51). Therefore, increased expression of Rpl31/37 and UPR
transcripts by monocytes/macrophages after DSS administration
may permit these cells to operate in hostile environments by
facilitating protein translation and maintaining key cellular
processes for survival.
Comparison of mRNA expression changes between colon
macrophage and monocytes revealed a highly conserved set
of genes that was independent of DSS-elicited inflammation.
A range of monocyte and neutrophil attracting chemokines
(Ccl7, Ccl8, Cxcl1) were more highly expressed in macrophages
compared tomonocytes from both steady state andDSS colitis. In
addition, expression of these chemokine transcripts were elevated
in monocytes from DSS treated vs. naïve mice. This shows
that expression of these chemokine transcripts was globally
elevated upon colitis, a feature that was also evident when
comparing human colon samples from active vs. quiescent IBD
and controls. There are numerous chemokines (CCL2, CCL7,
CCL8, and CCL12) that have been reported to recruit CCR2+
classical monocytes (7, 9). Of these, CCL2 is known to be
an important ligand for CCR2, though its role in colitis is
unclear, as DSS treated Ccl2−/− mice have been shown to
develop either exacerbated or ameliorated colitis (52, 53). In
contrast to other monocyte chemokines, we found that Ccl2
expression was equivalent between monocytes and macrophages.
However, interestingly, Ccl2 expression was actually reduced in
both monocytes and macrophages when comparing populations
before and after DSS. This suggests that macrophages and
monocytes are not the key source of CCL2 release during colitis.
The importance of CCL7, CCL8, CCL12, and CXCL1 to mediate
colitis inflammation, and the consequence of enhancedmonocyte
expression of these chemokines on pathology, is not known.
Although it has been reported that CD169+macrophages express
Ccl2, Ccl7, and Ccl8 during colitis (the contribution of monocytes
was not considered) (9, 54), and analysis of colon IBD sections
has suggested CCL8 as the greatest up-regulated chemokine
released from inflammatory cells (55). Therefore, as our study
directly compare transcriptomes of intestinal monocytes and
macrophages in both naïve and inflamed settings, we propose
that colon macrophages in colitis are important sources of
CCL7/8 and that, in addition, monocytes in inflamed settings
possess an increased ability to express Ccl7/8 that enables further
monocyte entry into inflamed tissue sites.
Together, our murine and human data suggest that monocyte
recruitment, and systemic priming of monocyte IL-1β release, are
key components involved in escalation of colon inflammation
in colitis. As such, targeted interference of monocyte recruiting
chemokines like CCL7, CCL8, or CXCL1 may help preserve the
steady state monocyte:macrophage balance that is disrupted in
pathological inflammatory states, such as IBD. Elegant tracking
studies have shown adult murine colon macrophages develop
from Ly6CHiCCR2+ blood monocytes, to Ly6C+CD11b+ colon
monocytes, to mature F4/80+CX3CR1Hi macrophages, a process
that is also characterised by a dramatic change in function and
phenotype as described above (2, 8, 10). Thus, modulation of
either monocyte or macrophage representation will likely change
the pro-inflammatory capacity of the GI tract.
CONCLUSION
In summary, we have shown accumulation of pro-inflammatory
monocytes in both murine colitis and human IBD, and
suggest that targeting these monocytes, or their recruitment by
macrophages, may represent a new and exciting future therapy
for intestinal inflammation.
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Supplementary Figure 1 | (A) Representative gating strategy by flow cytometry
to identify Live/singlet/Lineage−/CD45+HLA-DR+ cells from colon lamina propria.
(B) The cellular component of blood was isolated from day 6 DSS treated or
drinking water controls and stimulated with 1µg/ml LPS and GolgiStop 1 µl/ml for
3 h. CD11b+CD68+Ly6CHi blood monocytes were identified by flow cytometry
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and assessed for the expression of TNF by intracellular staining, n = 12–15 mice
per group analysed by linear regression of three independent experiments.
Supplementary Table 1 | qPCR colon biopsy sample patient demographics.
Twelve healthy control, 12 quiescent IBD, and 19 active IBD colon biopsy
specimens from 8 healthy control, 11 quiescent IBD, and 17 active IBD patients
attending for colonoscopy were obtained for RNA extraction and RT-qPCR
analysis. Patient records were reviewed for demographic, IBD location and
disease behaviour by Montreal classification. IM, Immunomodulatory drugs; MTX,
methotrexate; ADA, adalimumab; IFX, infliximab; 6′MP, 6-mercaptopurine; 5′ASA,
5′aminosalicylic acid. Montreal classification for CD: A1, age at onset <16 years;
A2, between 17 and 40 years; A3, >40 years. L1, ileal disease location; L2,
colonic disease location; L3, ileocolonic disease location. B1, inflammatory
phenotype; B2, stricturing phenotype; B3, penetrating phenotype. Montreal
classification for UC: E1, proctitis; E2, rectosigmoid disease; E3, disease proximal
to the splenic flexure. CD, Crohn’s disease; UC, ulcerative colitis. # Patient ID is
the identifier allocated to each individual providing tissue, such that donors that
gave more than 1 sample can be identified.
Supplementary Table 2 | Flow cytometry antibody details.
Supplementary Table 3 | qPCR Primer details.
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